Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic files first DES (drug-eluting stent) PMA (Pre-market Approval) module:

This article was originally published in Clinica

Executive Summary

Medtronic has initiated efforts to take its Endeavor drug-eluting stent (DES) to the US market, after submitting to the FDA the first of four premarket approval (PMA) modules for the device. The ABT-578-coated stent, which is used to prevent coronary restenosis, made its market debut in Europe in August this year. The company said it planned to file the remaining PMA modules over the coming year, during which time it should have obtained the necessary data to support the product. While several companies sell DESs in Europe, only Boston Scientific and Johnson & Johnson have gained approval to sell such devices in the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT056640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel